Injectable mepivacaine hydrochloride for veterinary regional anaesthesia is processed as an aqueous solution with active concentrations of 10 mg/mL, 20 mg/mL, or 30 mg/mL; the hydrochloride salt is selected because it is freely soluble in water at 25 °C, while the free base partitions into lipid only after tissue carbon dioxide raises the local pH above 7.0. The ionisation equilibrium is governed by a pKa of approximately 7.6; at formulation pH 4.5–5.5 the amidine nitrogen is protonated, ensuring complete dissolution in Water for Injection, whereas the uncharged fraction necessary for axonal membrane diffusion is generated at the injection site. Preparation begins with dissolving the active pharmaceutical ingredient in 80–90% of final-volume WFI at 20–30 °C under a nitrogen overlay to limit dissolved oxygen contact with the amide linkage. The pH is adjusted with 0.1 N hydrochloric acid or 0.1 N sodium hydroxide to a target of 4.8–5.2, and tonicity is corrected with sodium chloride to 285–320 mOsm/kg. Clarification is performed through a 0.45 μm polypropylene prefilter followed by a 0.22 μm polyethersulfone sterilising-grade membrane; the filter chain must be integrity-tested before and after filling by bubble point or diffusive flow according to the filter manufacturer's validation report. Fill-finish is carried out in an ISO 14644-1:2015 Class 5 environment using Type I borosilicate glass vials and chlorobutyl elastomeric closures. Where terminal heat sterilisation is selected, a cycle of 121 °C for 15 minutes is qualified by thermal mapping of the load; published data for terminal moist heat stability of mepivacaine HCl under this exact container closure configuration is limited, so batch release requires assay and pH shift verification after autoclaving. Terminal product testing includes HPLC assay for mepivacaine hydrochloride, related compounds by gradient elution, sterility by USP ⟨71⟩, bacterial endotoxins by USP ⟨85⟩ with a route-specific limit derived from the smallest species body weight, particulate matter by USP ⟨788⟩, pH, osmolality, and extractable volume. The finished injection is a single-dose or multi-dose parenteral for infiltration, nerve block, or epidural administration in species-specific protocols. Batch-to-batch variance in pH shift from terminal sterilisation has been observed when stopper lots released water-soluble acidic extractables; stopper lot screening with water extractable studies is therefore mandatory before sealing line qualification.

What Controls Blend Segregation in Direct Compression of 20 mg Veterinary Mepivacaine HCl Tablets?

Direct compression of mepivacaine HCl into oral tablets is limited by the API’s particle size distribution and the low mass fraction in a typical 250 mg core. A pilot-scale formula containing 20 mg mepivacaine HCl per tablet, corresponding to 8.0% w/w, is pre-blended with lactose monohydrate DFE having a median particle size of 110–150 μm at a 1:9 ratio for 10 minutes in a twin-shell diffusion blender at 25 rpm. Crospovidone 2.0% w/w and microcrystalline cellulose 20.0% w/w are then added as a secondary pre-mix; magnesium stearate 0.5% w/w is added last and blended for only 3 minutes to avoid overlayering of hydrophobic lubricant on the active particles. The compressible blend is pressed on a 10-station rotary tablet press with a target hardness of 60–80 N and friability not more than 1.0% using the friability method in USP ⟨1216⟩. Agglomeration of fine API particles during the initial pre-blend is the dominant cause of content uniformity failure; when a vertical blender is used instead of a twin-shell diffusion blender, the batch must be sampled at 20 distinct points after 10 minutes and again after 30 minutes to establish the optimum mixing window. Swirl or centrifugal sampling from a free-fall mixer is not accepted for release because it under-reports segregation at the hopper drawdown boundary. Dissolution testing for this veterinary oral tablet is not defined by a compendial monograph; method development under USP ⟨711⟩ Apparatus 2 with 900 mL pH 6.8 phosphate buffer is used as an investigative tool, but published data for oral mepivacaine solid-dose bioavailability is limited. Consequently, the release specification is based on content uniformity under USP ⟨905⟩ with an acceptance value not more than 15, assay 95.0–105.0% of labelled strength, disintegration under USP ⟨701⟩ not more than 15 minutes in water at 37 °C, and Karl Fischer moisture under USP ⟨921⟩ Method Ia not more than 2.0% w/w. The terminal product is a film-coated tablet; coating with hydroxypropyl methylcellulose occurs in a pan coater at a spray rate not exceeding 15 g/min and inlet air temperature not more than 65 °C to limit surface pockmarking and edges that increase friability. Granulation must be substituted if the API batch exhibits an excessive fraction of particles below 20 μm because static adhesion to blender walls produces sub-potent cores.

In multi-dose vial configurations intended for repeat-puncture withdrawal, mepivacaine hydrochloride is compounded at 20 mg/mL with either methylparaben 0.1% w/v or benzyl alcohol 0.9% v/v depending on target species; benzyl alcohol is excluded from feline formulations because documented adverse reactions in cats impose a practical upper limit below 0.1% v/v. Preservative efficacy is confirmed by USP ⟨51⟩, but the method must be conducted after container-closure equilibration because paraben esters partition into chlorobutyl rubber stoppers and lose solution activity within 14 days of filling. The formulation is prepared by dissolving mepivacaine HCl in WFI, adding the preservative at the final 10% of target volume to minimise evaporative loss during vacuum-assisted mixing, adjusting pH to 4.5–5.0, and making isotonic with sodium chloride to 300 mOsm/kg. Filtration is performed through a 0.22 μm PVDF membrane after preservative addition because polyethersulfone membranes have shown measurable methylparaben binding in high-throughput process simulations; the membrane manufacturer’s compatibility report should specify the maximum filtered volume per 10 cm² effective filtration area before saturation. The solution is filled into 50 mL or 100 mL Type I glass vials under nitrogen and closed with coated chlorobutyl stoppers. Terminal moist heat sterilisation at 121 °C for 15 minutes is applicable when the stopper lot has passed a leachable vapour test for formaldehyde and volatile organic acids; otherwise aseptic filtration is used to avoid pH drift from closure-derived extractables. Batch-to-batch variability in stopper siliconisation affects extractable volume and subvisible particle counts, so USP ⟨788⟩ light obscuration is performed after 24 hours of vial inversion. The finished product is a preserved multi-dose injection for aseptic withdrawal; in-use stability after first puncture is limited by the preservative reserve and must be validated under USP ⟨51⟩ at the intended number of withdrawals.

When Roller Compaction Replaces Direct Compression for Low-Dose Capsule-Filled Granulate

Capsule manufacture with mepivacaine HCl at 10 mg per capsule requires a granulation step because direct fill of low-mass API into hard gelatin capsules produces unacceptable weight variation and unacceptable aerosolised dust exposure. A dry granulation route is selected over wet granulation because the amide-linked active is susceptible to hydrolysis when residual moisture exceeds 2.0% w/w during tray drying, and because a solvent-free process avoids the need to requalify residual solvent under USP ⟨467⟩. The pre-blend consists of mepivacaine HCl 10 mg, mannitol 120 mg, microcrystalline cellulose 80 mg, crospovidone 10 mg, and colloidal silicon dioxide 2 mg per capsule; this gives a fill weight of approximately 222 mg. Blending is performed in a bin blender at 12 rpm for 20 minutes, followed by roller compaction at roll pressure 30–50 bar, roll speed 5–8 rpm, and screen size 0.8 mm. Ribbons outside the desired thickness range are milled and refed as a recycled fraction not exceeding 10% w/w to avoid densification drift that reduces granulate compressibility. The milled granulate is lubricated with sodium stearyl fumarate 1.0% w/w for 3 minutes and filled into size 3 hard gelatin capsules using a dosing disc machine at 60,000 capsules/hour. In-process control samples are taken at beginning, middle, and end of the filling run; content uniformity is measured by USP ⟨905⟩ on 30 capsules, and the acceptance value must not exceed 15. Disintegration testing uses USP ⟨701⟩ with water at 37 °C and a limit of 15 minutes; this is supplemented by moisture under USP ⟨921⟩ Method Ia not more than 2.0% w/w. Dissolution testing is not included as a routine release method because no established veterinary oral mepivacaine product-specific dissolution criterion exists; batch development uses USP ⟨711⟩ Apparatus 2 at 50 rpm in 0.1 N HCl only to detect formulation changes. The terminal product is a hard gelatin capsule intended for investigational oral administration in large animals under veterinary supervision; published bioavailability data for this configuration is limited, so dose verification relies on assay and content uniformity rather than pharmacokinetic extrapolation.

Bulk mepivacaine HCl powder for extemporaneous sterile injection is handled under controlled relative humidity not exceeding 40% RH at 20–25 °C because the crystalline material becomes adherent to stainless steel scoops and glove surfaces when surface moisture rises above 0.5% w/w. The powder is triturated with sodium chloride in a pre-weighed 1:10 ratio before dissolution; geometric dilution in a glass mortar with low static charge is used rather than simultaneous addition to WFI, because simultaneous addition generates undissolved aggregates that clog 0.22 μm sterilising filters. In cleanroom operations, the dispensed API is transferred into an ISO 14644-1:2015 Class 5 low-particulate enclosure and dissolved under aseptic conditions in WFI at 30–35 °C with gentle magnetic stirring for 10–15 minutes. The solution is made isotonic with sodium chloride to 290–310 mOsm/kg and passed through a 0.22 μm polyethersulfone syringe filter with prefiltration through a 0.45 μm polypropylene depth filter; filter integrity is tested by bubble point before and after the fill. Each sterile unit is filled into a 5 mL Type I glass vial and lyophilised to a moisture content not more than 1.0% w/w. Residual moisture after lyophilisation is measured by coulometric Karl Fischer titration under USP ⟨921⟩ Method Ic; headspace oxygen is maintained below 2.0% v/v by nitrogen backflush before stoppering. The terminal product is a sterile dry powder for reconstitution with 1.0 mL diluent to yield a 20 mg/mL injection; reconstituted storage time is limited to 24 hours at 2–8 °C because preservative is absent and microbial ingress risk cannot be excluded after first puncture. Sterility is confirmed by USP ⟨71⟩; bacterial endotoxin testing under USP ⟨85⟩ is based on the intended animal body weight; particulate matter after reconstitution is tested by USP ⟨788⟩. Published data for gamma irradiation or dry-heat sterilisation of mepivacaine HCl bulk powder is limited, so sterile filtration of the reconstituted solution remains the preferred terminal microbial reduction route when a sterile dry powder is not required by the marketing authorisation.

Terminal Moist Heat Sterilization and Amide Bond Stability Ranges

The thermal sterilisation boundary for mepivacaine HCl solutions is defined by three measurable process outputs: pH shift, related compound formation, and closure extractable release. Steam cycles of 121 °C for 15 minutes are feasible when the pre-autoclave pH is maintained at 4.5–5.0 and the container headspace oxygen is below 5.0% v/v. At pH values above 6.0, the amide linkage becomes more susceptible to hydrolysis at high temperature, and the solution may exhibit visible yellowing after repeated cycles; published kinetic data for mepivacaine HCl under all buffer species is limited, so each autoclave cycle must be monitored with a load challenge containing a worst-case pH and headspace configuration. Batch-to-batch variance in chlorobutyl stopper formulation has produced stopper extractables that lower the post-autoclave pH by 0.2–0.4 units, shifting the ionised fraction and altering preservative ionisation in multi-dose vials. Release after terminal sterilisation therefore includes pH measurement at 25 °C, related compound assay by HPLC according to the compendial method, and stopper leachables screening by gas chromatography-mass spectrometry after solvent extraction. If the pH shift exceeds 0.3 units, the batch is rejected or re-processed only after an approved deviation because the uncharged fraction at the injection site may be altered and the preservative efficacy may fall outside USP ⟨51⟩ acceptance. Aseptic filtration through 0.22 μm membranes remains the alternative for heat-sensitive or preservative-loaded multi-dose solutions; however, aseptic filtration must be followed by sterility test USP ⟨71⟩ and cannot compensate for inadequate upstream bioburden control. The terminal product in this segment is a terminally sterilised single-dose injection; it is released only after 14 days of accelerated storage at 40 °C ± 2 °C and 75% ± 5% RH shows no visible precipitation and total related compounds below the compendial threshold.

Premix concentrates require sodium acetate buffering at pH 4.8 to prevent free-base precipitation

A concentrated premix solution of 50 mg/mL mepivacaine HCl is prepared for subsequent dilution by a veterinarian or compounding pharmacist. The formulation uses sodium acetate buffer at 20 mM to hold pH at 4.8 ± 0.2, because at pH above 6.2 the unionised free base begins to precipitate and the solution becomes turbid when stored at 2–8 °C. The hydrochloride salt is dissolved in WFI at 20–25 °C under nitrogen; the buffer is added only after complete dissolution to avoid local pH excursions that promote transient precipitation. Tonicity is adjusted with sodium chloride to 300–350 mOsm/kg, and the solution is filtered through a 0.45 μm prefilter followed by a 0.22 μm PVDF membrane; PES is avoided because concentrated paraben systems and high acetate concentrations may exceed the manufacturer’s recommended pH and solvent compatibility window. The filtered concentrate is filled into 10 mL Type I glass ampoules or vials and terminally sterilised at 121 °C for 15 minutes if the pH is below 5.0. Terminal product testing includes assay by HPLC, pH, osmolality, particulate matter by USP ⟨788⟩, sterility by USP ⟨71⟩, and bacterial endotoxins by USP ⟨85⟩. Dilution instructions require addition to 0.9% w/v sodium chloride injection with mixing by gentle inversion; vigorous mechanical shaking is avoided because air entrapment increases subvisible bubble counts during USP ⟨788⟩ testing. The end product after dilution is a 1.0% w/v, 2.0% w/v, or 3.0% w/v injection depending on clinical protocol; no preservative is introduced at the dilution stage, so the diluted solution is used within 6 hours at room temperature or 24 hours at 2–8 °C.